India’s famous Drug firm Hetero launched Biosimilar Adalimumab in India. This is one of the best drug can be used for the treatment of rheumatoid arthritis and other auto-immune disorders. The medicine is introduced under the brand name ‘Mabura’.
This new medicine is a a biosimilar version of AbbVie’s Humira. This medicine will be marketed and distributed in India by Hetero Healthcare company. This will be made at the company’s Hyderabad facility.
Adalimumab is most commonly sold under the trade name Humira. This is one of the best available drug to treat various conditions like Crohn’s disease, ulcerative colitis, chronic psoriasis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurative and juvenile idiopathic arthritis.
This is a TNF-inhibiting and anti-inflammatory medication. This works in a way, it binds to tumor necrosis factor-alpha (TNFα) and reduces inflammatory response. Treatment with adalimumab may increase the chance of infections as body’d natural immunity is suppressed.
In 2014, the first adalimumab biosimilar came to Indian market for just $200. Two years later Torrent Pharmaceuticals launched second biosimilar. This drug usually costs approximately $4370 per month. Hetero did not disclose the price of the new medicine. Hetero Biosimilar Adalimumab will be under the brand name ‘MaburaTM’ in India.
MaburaTM will be available to purchase as a pre-filled syringe (PFS) of 40mg. This can be administered subcutaneously.